|Bid||20.34 x 900|
|Ask||20.98 x 2900|
|Day's Range||19.96 - 21.00|
|52 Week Range||15.64 - 47.11|
|Beta (3Y Monthly)||2.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.38|
Nektar Therapeutics (NASDAQ:NKTR) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President and Chief Commercial Officer. John will also serve as a member of the Company's Executive Committee reporting directly to President and CEO, Howard W. Robin.
SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, ...
Shares of Nektar Therapeutics popped Monday after the biotech company's Bristol-Myers Squibb-partnered regimen continued to show promise in never-before-treated melanoma patients.
The company released clinical data that raised hope about a drug-development program that has encountered manufacturing problems.
SAN FRANCISCO, Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammatory conditions. The data, which were presented at the 2019 Annual Meeting of the American College of Rheumatology in Atlanta, show that treatment with NKTR-358 led to a marked and selective dose-dependent expansion in the numbers and proliferative capacity of FoxP3+CD25bright Treg cells, and a measurable activation of Treg cells. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from reduced numbers and impaired function of immune-regulating Treg cells.
New Data Presented for Previously Untreated Metastatic Melanoma Patients in PIVOT-02 Study of Bempegaldesleukin with Nivolumab Additional Preclinical Data Presentations Showcase Nektar's Immuno-Oncology ...
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Nektar (NKTR) delivered earnings and revenue surprises of 23.29% and 11.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO , Nov. 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019 . Cash and investments in marketable ...
Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength. Here are the key catalytic event a biotech investor ...
SAN FRANCISCO , Nov. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management ...
SAN FRANCISCO , Oct. 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019 , after the close of U.S.-based ...
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Nektar Therapeutics (NKTR) is conducting a trial that will test NKTR-255 in patients with relapsed-refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), explains biotech specialist John McCamant, editor of The Medical Technology Stock Letter.
Longtime investors know the stock market is forward-looking. That means a stock’s share price is more a reflection of what investors collectively think the company will do in the future than what it did ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between February 15, 2019 through August 8, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the Company") ...
NEW YORK, NY / ACCESSWIRE / October 17, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR). Such investors ...
Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). According to the complaint, Nektar is a biopharmaceutical company that develops medicines in areas of high unmet medical need, including therapies for cancer, autoimmune disease, and chronic pain. In the PIVOT-02 clinical study, Nektar evaluates the benefit, safety, and tolerability of combining NKTR-214 with Opdivo, an antibody, in collaboration with Bristol-Meyers Squibb Company.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (NKTR) (“Nektar”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Nektar securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). REMINDER: Investors who purchased Nektar securities during the Class Period may, no later than October 18, 2019, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, Nektar is a biopharmaceutical company that develops medicines in areas of high unmet medical need, including therapies for cancer, autoimmune disease, and chronic pain.
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a motion for appointment as lead plaintiff in a securities class action on behalf of investors that purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NKTR) between February 15, 2019 and August 8, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you purchased Nektar securities, and/or would like to discuss your legal rights and options please visit Nektar Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.